Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
Summary
Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committ...
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.